Skip to main content
Fig. 2 | Health Economics Review

Fig. 2

From: Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in the management of atrial fibrillation in Argentina

Fig. 2

Tornado sensitivity analysis of the incremental cost-effectiveness ratio of Apixaban compared with warfarin. The solid vertical line represents the base-case incremental cost-effectiveness ratio. In the vertical lines are depicted the range obtained for a variable while the others are constant. MI: myocardial infarction; CV: cardiovascular hospitalization; ICH: intracranial hemorrhage; Monitoring visit: applied only to patients treated with warfarin; AFtrialRate: treatment´s discontinuation rate; OMB: other major bleed

Back to article page